Pittsburgh plasma p‐tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community

Authors:

Abstract
INTRODUCTION: Most available phosphorylated tau (p‐tau)217 immunoassays have similar performance. It is unclear if this is due to the use of the same antibody (the “ALZpath antibody”). We established and evaluated a novel p‐tau217 assay that uses an alternative antibody and benchmarked the results against ALZpath‐p‐tau217. METHODS: After development and analytical validation of the University of Pittsburgh (“Pitt‐p‐tau217”) method, clinical verification was performed in three independent cohorts ( n = 363). RESULTS: Pitt‐p‐tau217 demonstrated high between‐run stability, linearity, and specificity. Clinically, Pitt‐p‐tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with area under the curve (AUC) = 0.94, and amyloid beta (Aβ) positron emission tomography (PET)–positive from Aβ PET–negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath‐p‐tau217 results. Both Pitt‐p‐tau217 and ALZpath‐p‐tau217 were slightly elevated in tau PET–positive versus tau PET–negative participants. Between‐assay correlations were up to 0.93. DISCUSSION: The new Pitt‐p‐tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of Alzheimer's disease, equivalent to the widely used ALZpath‐p‐tau217. Highlights: We designed and developed an alternative assay to quantify plasma phosphorylated tau (p‐tau)217, aiming to enhance accuracy and enable early detection of Alzheimer's disease (AD). Comprehensive analytical and clinical validation demonstrated that the new p‐tau217 assay is a valuable and affordable resource for investigating AD pathophysiology. The new p‐tau217 assay showed similar performance to the established ALZpath assay in staging and monitoring early AD.
All Related Versions
Funding Information
  • National Institute on Aging (R01 AG083874, U24AG082930, P30 AG066468, RF1 AG077474, R01 AG083156, R37 AG023651, R01 AG025516, R01 AG073267, R01 AG075336, R01 AG072641, P01 AG025204)
  • National Institute of Neurological Disorders and Stroke (U01 NS131740, U01 NS141777)
  • National Institute of Mental Health (R01 MH108509)

This publication has 41 references indexed in Scilit: